Stenocare A/S cultivates, produces, imports, distributes, and sells prescription-based medical cannabis products to patients in Denmark and internationally. It offers medical cannabis oil products, including THC, THC/CBD, and CBD, as well as CBD100 oil products. The company was incorporated in 2017 and is based in Randers, Denmark.…
Stenocare (CPH: STENO) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 0.5900 DKK on 20 November 2026, down 73.1% over 52 weeks. Its 52-week range is 0.5000 DKK to 2.800 DKK: the price is 78.9% below the high and 18.0% above the low.
Its market capitalisation is 25.49M DKK.
Stenocare reports return on equity of -25.2%, an operating margin of -10.5% and revenue up 53.2% year over year.
Its debt exceeds its cash by 142.08K DKK, a debt-to-equity ratio of 0.21. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.